Scarica l'app Stockscreener
0.8877
1.37%
-0.0123
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsEarnings Performance Report & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow Jones2025 Geopolitical Influence & Entry and Exit Point Strategies - ulpravda.ru
What hedge fund moves indicate for Citius Pharmaceuticals Inc. (47N0) stockShare Buyback & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. stock continue upward momentumJuly 2025 Drop Watch & Technical Entry and Exit Alerts - ulpravda.ru
Is Citius Pharmaceuticals Inc. stock a top momentum playPortfolio Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
What technical charts say about Citius Pharmaceuticals Inc. stockFed Meeting & Fast Entry and Exit Trade Plans - ulpravda.ru
How Citius Pharmaceuticals Inc. (47N0) stock expands through international marketsMarket Growth Report & Consistent Profit Trade Alerts - ulpravda.ru
Can Citius Pharmaceuticals Inc. (47N0) stock resist broad market declinesJuly 2025 Big Picture & High Conviction Investment Ideas - ulpravda.ru
Will Citius Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Sentiment & Weekly Stock Breakout Alerts - ulpravda.ru
User | poteaudailynews.comCitius Pharmaceuticals, Inc.Common Stock (Nasdaq:CTXR) Stock Quote - FinancialContent
Portfolio Update: Can Citius Pharmaceuticals Inc 47N0 stock resist broad market declinesJuly 2025 Chart Watch & Safe Capital Allocation Plans - moha.gov.vn
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus
Citius Oncology announces pricing of $9 million public offering - MSN
Fibonacci Retracement Aligns with Support in Thomas Scott India LimitedAnalyst Upgrades & Small Capital Trading Tips - earlytimes.in
Is Citius Pharmaceuticals Inc 47N0 a good long term investmentMarket Sentiment Report & Free Long-Term Investment Planning - earlytimes.in
Citius Pharmaceuticals Inc (CTXRW) Fundamental Analysis - Meyka
Market Outlook: What dividend safety score for Citius Pharmaceuticals Inc stockAnalyst Downgrade & Risk Managed Investment Strategies - moha.gov.vn
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Dow Gains Over 100 Points; US Jobless Claims Decline - Benzinga
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus - Sahm
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Citius Pharmaceuticals Inc. Full Year Loss Decreases - Nasdaq
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals, Inc. reports fiscal year 2025 financial results and provides business update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. - Investing.com
CTXR: LYMPHIR's U.S. launch marks a pivotal year, with strong capital raises and ongoing pipeline progress - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
How interest rate cuts could boost Citius Pharmaceuticals Inc. stockShort Setup & Stock Portfolio Risk Management - Улправда
Why Citius Pharmaceuticals Inc. stock remains resilientPortfolio Performance Report & Technical Pattern Based Buy Signals - Улправда
Is Citius Pharmaceuticals Inc. (47N0) stock a safe buy pre earningsExit Point & Daily Oversold Bounce Ideas - Bölüm Sonu Canavarı
Can Citius Pharmaceuticals Inc. stock resist market sell offsWeekly Stock Summary & Proven Capital Preservation Tips - Улправда
Sell Signal: How Citius Pharmaceuticals Inc. stock trades before earnings2025 Biggest Moves & Daily Growth Stock Investment Tips - Улправда
What analyst consensus says on Citius Pharmaceuticals Inc. stockJuly 2025 Recap & Low Risk High Win Rate Picks - DonanımHaber
Analyst Calls: Will Citius Pharmaceuticals Inc. stock maintain dividend yieldInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
Will Citius Pharmaceuticals Inc. (47N0) stock outperform energy sector in 2025July 2025 Big Picture & Free Weekly Chart Analysis and Trade Guides - DonanımHaber
Will Citius Pharmaceuticals Inc. stock see insider buyingJuly 2025 Chart Watch & Real-Time Buy Signal Alerts - DonanımHaber
Citius Pharmaceuticals Earnings Notes - Trefis
Is Citius Pharmaceuticals Inc. stock positioned for digital transformationOil Prices & Real-Time Volume Surge Alerts - ulpravda.ru
Why Citius Pharmaceuticals Inc. stock remains a top recommendationJuly 2025 Reactions & Real-Time Chart Breakout Alerts - Улправда
Quarterly Earnings: How interest rate cuts could boost Citius Pharmaceuticals Inc. stockAnalyst Upgrade & Accurate Entry/Exit Alerts - Улправда
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology (Nasdaq: CTOR) raises $18M at-the-market to fund LYMPHIR - Stock Titan
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Finviz
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):